Flow Neuroscience

Flow Neuroscience is a Swedish neurotechnology company headquartered in Malmö that has developed an integrated digital therapeutics platform for treating major depressive disorder at home. The company's core product combines a CE-marked transcranial direct current stimulation (tDCS) headset with a companion smartphone application that delivers structured behavioral therapy sessions alongside brain stimulation. This closed-loop approach is designed to enhance neuroplasticity through repeated stimulation of the prefrontal cortex while simultaneously reinforcing cognitive behavioral therapy principles through guided digital sessions. By pairing hardware and software into a single prescribed treatment pathway, Flow Neuroscience enables clinicians to remotely monitor and support patients outside of traditional clinical settings.

Flow Neuroscience has secured CE marking for its tDCS device, establishing regulatory credibility in the European market and positioning the product as a clinically sanctioned therapeutic rather than a consumer wellness tool. The company has raised $12 million in Series A funding, capital that is expected to accelerate clinical validation efforts, expand its commercial footprint, and support further development of its digital platform. Their treatment protocol is backed by clinical research demonstrating meaningful reductions in depressive symptoms, lending scientific weight to the product's adoption among psychiatrists and mental health practitioners. These milestones place Flow Neuroscience among a small but growing cohort of digital mental health companies that have successfully bridged regulated hardware and software-based care delivery.

Flow Neuroscience represents an important proof of concept for the broader neurotechnology industry, demonstrating that non-invasive brain stimulation can be made accessible, scalable, and clinically meaningful outside hospital environments. Their model challenges the traditional boundaries between medical devices and digital health, offering a template for how neuromodulation can be embedded into everyday therapeutic workflows. As demand for accessible mental health treatment continues to outpace the capacity of conventional care systems, companies like Flow Neuroscience highlight the potential of neurotech to address large-scale psychiatric unmet needs. Their progress also reinforces the commercial viability of prescription digital therapeutics that integrate hardware, software, and behavioral science into a unified treatment paradigm.